Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Ophthalmology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Diabetic Macular Edema Clinical Trials

A listing of Diabetic Macular Edema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (65) clinical trials

Anti-VEGF Treatment for Prevention of PDR/DME

Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular permeability including diabetic macular edema (DME). While there is strong evidence that PDR outcomes are markedly reduced in eyes that are treated ...

Phase

Combination OZURDEX & LUCENTIS vs. OZURDEX Monotherapy in Incomplete-Responders With Diabetic Macular Edema

Hypothesis Pseudophakic center-involved DME eyes with incomplete response to 3-6 anti-VEGF injections (i.e., RBZ, BCZ or IAI) will have similar visual acuity gains, as assessed with AUC analysis (change from baseline randomization (Time 0) BCVA letters through 24 weeks 1 week), with a combination treatment regimen consisting of RBZ (0.5 ...

Phase

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

Efficacy of aflibercept for diabetic macular edema was demonstrated in the phase III, VIVID and VISTA studies. In these studies, aflibercept was injected using the fixed dosing regimen that an intravitreal injection was performed 5 times every 4 weeks and then every 8 weeks. Although the efficacy was comparable to ...

Phase

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema

Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively. The main objectives of this observational cohort field study are to evaluate effectiveness of intravitreal aflibercept and to describe follow-up as ...

Phase N/A

A Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)

Phase

Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema

Diabetic macular edema (DME) is the leading cause of blindness among people of working age. Treatment of DME included blood pressure and glycemic control, grid laser, intravitreal injection of steroids (acetonide of triamcinolone, dexamethasone implant, fluocinolone implant) or anti-Vascular endothelial growth factor (VEGF) therapy (Bevacizumab, Ranibizumab, Aflibercept) (2015). The advent ...

Phase N/A

Trial of Switching Between Intravitreal Bevacizumab (Avastin )& Intravitreal Dexamethasone (Ozurdex ) for Persistent Diabetic Macular Oedema

A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin) and Intravitreal Dexamethasone (Ozurdex) for Persistent Diabetic Macular Oedema (SwitchDMO)

Phase

Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa

Introduction Diabetic retinopathy (DR) is the most common complication among the 300,000 Danish patients with diabetes. Amongst those with diabetes, diabetic macular edema (DME) is a leading cause of visual impairment and will in time affect 29% of all patients. It was established by the Early Treatment Diabetic Retinopathy Study ...

Phase

Treatment for CI-DME in Eyes With Very Good VA Study

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent ...

Phase

Identifying Patients With Unrecognized Treatable Diabetic Macular Edema

This trial will assess the incidence of new and/or undiagnosed diabetic macular edema (DME) in diabetic patients that undergo a DME screening exam. The screening exam will consist of medical history, Electronic ETDRS visual acuity assessment, SD-OCT and color fundus photography

Phase N/A